T-Cell Revolution | Generation Bio's pivot to T-cell targeting for autoimmune diseases promises innovative treatments, potentially addressing previously undruggable targets |
Moderna Partnership | Collaboration with Moderna validates technology and provides financial cushion, offering up to $1.8 billion in milestone payments and synergistic development |
Financial Landscape | Despite $158 million cash reserves, GBIO trades below cash position. Canaccord Genuity sets $9 price target, while JMP Securities maintains Market Perform rating |
Strategic Roadmap | Company aims for lead target nomination by mid-2025 and IND filing in 2026, with Phase 1 trials expected between late 2026 and early 2027 |
Metrics to compare | GBIO | Peers Peers - average of corresponding metrics from companies closely matching GBIO: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipGBIOPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 55.7% | |
Fair Value Upside | Unlock | 0.0% | 8.1% | Unlock |